SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : INHL - Inhale Therapeutics - Pulmonary Insulin!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: deeno who wrote (196)12/18/2001 2:04:44 PM
From: TheAlaskan  Read Replies (1) of 225
 
Measure Twice Cut Once

seems to be a better strategy especially if the product will be immediately fielded with rapid and extensive use. The approach seems rational and wise in light of this expectation. I think it is prudent to produce the data and file it with the FDA rather than have it requested later.

I do not think Pfizer would have added Exubera to their press releases if they did not think it was going to be a revenue producer for them. The market over reaction today looks like a good buying opportunity.

The Alaskan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News